Ampio Pharmaceuticals (AMPE)
OTHER OTC:AMPE
Want to see AMPE full AI Analyst Report?
AMPE Stock Chart & Stats
$0.21
$0.00(0.00%)
At close: 4:00 PM EST
$0.21
$0.00(0.00%)
Day’s Range― - ―
52-Week Range<$0.01 - $0.64
Previous CloseN/A
Volume38.00
Average Volume (3M)1.58K
Market Cap
$207.88K
Enterprise Value-$3.61M
Total Cash (Recent Filing)$4.09M
Total Debt (Recent Filing)$274.00K
Price to Earnings (P/E)―
Beta29.23
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,135,358
10 Day Avg. Volume4,379
30 Day Avg. Volume1,578
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.49
Price to Sales (P/S)0.00
P/FCF Ratio-0.19
Enterprise Value/Market Cap-17.35
Enterprise Value/Revenue-14.72
Enterprise Value/Gross Profit-14.72
Enterprise Value/Ebitda0.38
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageLow leverage indicates that the company has not overburdened itself with debt, which can be advantageous in maintaining financial flexibility and reducing risk during periods of financial distress.
Asset StabilityMaintaining a positive equity ratio suggests that despite financial challenges, the company has managed to keep its assets stable, which is crucial for long-term operational sustainability.
Innovative Treatment ApproachFocusing on innovative treatments for prevalent conditions like osteoarthritis positions Ampio to potentially capture significant market share if successful, providing a strong foundation for future growth.
Bears Say
Zero RevenueThe lack of revenue generation over an extended period highlights significant challenges in commercializing products, which is critical for sustaining operations and achieving profitability.
Negative Cash FlowPersistent negative cash flow indicates the company struggles to generate sufficient cash from its operations, posing risks to its ability to finance ongoing activities and future growth.
Ongoing LossesContinued operating losses suggest difficulties in achieving profitability, which can hinder the company's ability to invest in research, development, and expansion efforts.
Ampio Pharmaceuticals News
AMPE FAQ
What was Ampio Pharmaceuticals’s price range in the past 12 months?
Ampio Pharmaceuticals lowest stock price was <$0.01 and its highest was $0.64 in the past 12 months.
What is Ampio Pharmaceuticals’s market cap?
Ampio Pharmaceuticals’s market cap is $207.88K.
When is Ampio Pharmaceuticals’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Ampio Pharmaceuticals’s earnings last quarter?
Currently, no data Available
Is Ampio Pharmaceuticals overvalued?
According to Wall Street analysts Ampio Pharmaceuticals’s price is currently Overvalued.
Does Ampio Pharmaceuticals pay dividends?
Ampio Pharmaceuticals does not currently pay dividends.
What is Ampio Pharmaceuticals’s EPS estimate?
Ampio Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ampio Pharmaceuticals have?
Ampio Pharmaceuticals has 1,135,358 shares outstanding.
What happened to Ampio Pharmaceuticals’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Ampio Pharmaceuticals?
Currently, no hedge funds are holding shares in AMPE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ampio Pharmaceuticals
Ampio Pharmaceuticals, Inc., headquartered in Englewood, Colorado, is a biopharmaceutical firm dedicated to advancing immunomodulatory therapeutics primarily for the management of osteoarthritis pain across the United States. Their developmental pipeline currently features several compounds: AP-013, an intra-articular injection, is undergoing Phase III clinical trials for knee osteoarthritis. Additionally, the company has multiple candidates addressing COVID-19: AP-017, an intravenous Ampion formulation, is in Phase II for adult COVID-19 patients who require supplemental oxygen; AP-019, an inhaled Ampion treatment, also in Phase II, targets adults experiencing respiratory distress from COVID-19; while AP-018, currently in Phase I, aims to treat individuals with persistent respiratory symptoms following COVID-19 infection.
Technical Analysis
Scinai Immunotherapeutics
―
Indaptus Therapeutics
―
PharmaCyte Biotech
―
Aditxt
―
Dermata Therapeutics
―
Ownership Overview
―
Insiders
―
Mutual Funds
0.04% Other Institutional Investors
99.96% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---